PMA device
Access Hybritech free PSA
Beckman Coulter, Inc. · Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions (MTG, Class III) · First FDA decision Feb 24, 2000, newest May 15, 2025Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
0
Naming "Access Hybritech"
MAUDE reports
8
Brand "Access Hybritech", since 2015
PubMed studies
11
Mentioning "Access Hybritech"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Access Hybritech free PSA
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- Access Hybritech free PSAPMA supplement
P970038-S046 · Decided May 15, 2025 · 286 days after receipt · Normal 180 Day Track
Device type: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions (MTG) · Laboratory Medicine & Pathology
- ACCESS HYBRITECH FREE PSA ASSAYPMA supplement
P970038-S012 · Decided Aug 13, 2008 · 78 days after receipt · Normal 180 Day Track
Device type: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions (MTG) · Laboratory Medicine & Pathology
P970038-S009 · Decided Sep 19, 2007 · 126 days after receipt · Normal 180 Day Track
Device type: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions (MTG) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Access Hybritech", any status and sponsor, newest update first.
No registered device study names "Access Hybritech".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Access Hybritech", and for the whole product code for context.
This brand
8 reports: 5 malfunction, 3 injury, 0 death
Whole product code MTG
108 reports: 107 malfunction, 1 injury, 0 death
Newest reports for this brand
- Access Hybritech PSAMalfunction
2122870-2026-00468 · Received Oct 6, 2026 · Event dated Sep 8, 2026
Device type: Single (Specified) Analyte Controls (Assayed And Unassayed) (JJX)
Device problem as coded: Low Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ACCESS HYBRITECH PSAInjury
9680746-2023-00008 · Received Nov 28, 2023 · Event dated Nov 6, 2023
Device type: Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers (LTJ)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ACCESS HYBRITECH P2PSAInjury
2122870-2023-00078 · Received Jun 20, 2023 · Event dated May 1, 2023
Device type: P2psa (OYA)
Device problem as coded: High Test Results
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Access Hybritech"[tiab]. The summary above synthesizes these.
- Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection.
Höti N, Lih TS, Dong M, et al. · Cancers (Basel) · 2023
- Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
Garrido MM, Marta JC, Ribeiro RM, et al. · In Vivo · 2021Comparative Study
- Multi-center analytical performance evaluation of the Access Hybritech® p2PSA immunoassay.
Sokoll LJ, Chan DW, Klee GG, et al. · Clin Chim Acta · 2012Evaluation Study, Multicenter Study
- Highly portable quantitative screening test for prostate-specific antigen at point of care.
Srinivasan B, Nanus DM, Erickson D, et al. · Curr Res Biotechnol · 2021
- Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA.
Vignati G, Giovanelli L · Int J Biol Markers · 2007Multicenter Study
- Comparison Between a New PSA Assay With the Well-Established Beckman Coulter Immunoassay: A Preliminary Report.
La Civita E, Fiorenza M, Jannuzzi G, et al. · Anal Sci Adv · 2025
- Prostate specific antigen assay standardization bias could affect clinical decision making.
Loeb S, Chan DW, Sokoll L, et al. · J Urol · 2008Research Support, Non-U.S. Gov't
- Stability of total prostate-specific antigen and free prostate-specific antigen after 10 years' storage.
Simanek V, Topolcan O, Karlikova M, et al. · Int J Biol Markers · 2018
- Prostate-specific antigen concentration in young men: new estimates and review of the literature.
Sutcliffe S, Pakpahan R, Sokoll LJ, et al. · BJU Int · 2012Research Support, Non-U.S. Gov't, Review
- CLSI EP17-A protocol: a useful tool for better understanding the low end performance of total prostate-specific antigen assays.
Moretti M, Sisti D, Rocchi MB, et al. · Clin Chim Acta · 2011
- Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer?
Oberpenning F, Hetzel S, Weining C, et al. · Eur Urol · 2003Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MTG.
- Elecsys free PSA, free PSA CalSetRoche Diagnostics Corp. · PMA 2023
- ARCHITECT Free PSAAbbott Laboratories · PMA 2020
- Dimension FPSA Flex Reagent CartridgeSiemens Healthcare Diagnostics · PMA 2018
- Dimension Vista Fpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Axsym Free PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000 & Immulite 2000 Free PsaSiemens Medical Solutions Diagnostics Limited · PMA 2010
- Atellica IM free PSA II (fPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
- IMMULITE 2000 Free PSASiemens Medical Solutions Diagnostics Limited · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.